Nelson Teng
Academic Appointments
- Associate Professor, Obstetrics & Gynecology - Gynecologic Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Women's Cancer Center 900 Blake Wilbur Dr 1st Floor MC 5854 Palo Alto, CA 94304 Tel Work (650) 498-6004 Fax (650) 498-7237
- Academic Offices
Personal Information Email Tel (650) 498-8080 Tel (650) 723-7334Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Gynecologic Cancer
- Cervix Cancer
- Cervix Cancer - Gynecologic Oncology
- Endometrial Cancer
- Endometrial Cancer - Gynecologic Oncology
- Fallopian Tube
Professional Education
| Residency: | UCLA Medical Center CA (1981) |
| Fellowship: | Stanford University School of Medicine CA (1984) |
| Board Certification: | Gynecologic Oncology, American Board of Obstetrics and Gynecology (1987) |
| Board Certification: | Obstetrics and Gynecology, American Board of Obstetrics and Gynecology (1985) |
| Internship: | UCLA Medical Center CA (1978) |
| Medical Education: | University Of Miami - School of Medicine FL (1977) |
Internet Links
Scientific Focus
Current Research Interests
Gynecologic Malignancies
Immunotherapy
Biologic Response Modifiers
New Drug Development
Antigenic specificities of human antibodies encoded by the VH4-34 gene
Clinical Trials
- Not Recruiting Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma
- Not Recruiting Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
- Recruiting Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
- Not Recruiting Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
- Not Recruiting Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Publications
- Taxol-oligoarginine conjugates overcome drug resistance in-vitro in human ovarian carcinoma. Gynecol Oncol. 2012; (1): 118-23
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012; (17): 6662-7
- Gynecologic malignancies in female-to-male transgender patients: the need of original gender surveillance. Am J Obstet Gynecol. 2011; (5): e9-e12
- Leukemia inhibitory factor downregulates human papillomavirus-16 oncogene expression and inhibits the proliferation of cervical carcinoma cells. Infect Dis Obstet Gynecol. 2011: 463081
- Prox-1, Podoplanin and HPV staining assists in identification of lymphangioma circumscriptum of the vulva and discrimination from vulvar warts. Histopathology. 2011; (6): 1274-7
- Squamous cell carcinoma arising from mature cystic teratoma of the ovary. Int J Gynecol Cancer. 2011; (3): 466-74
Help
Trial Administration